Sanjivani Paranteral Reports Strong Growth Amid Valuation Concerns and Debt Challenges

Sanjivani Paranteral, a microcap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an evaluation adjustment that reflects notable shifts in its financial metrics. The company reported a positive financial performance for the quarter ending March 2025, with a significant increase in its score over the past three months. Key indicators include a profit after tax (PAT) of Rs 4.09 crore, which has shown a growth rate of 40.55%, and net sales reaching Rs 18.18 crore, marking a peak for the quarter.
However, the company faces challenges as indicated by its debtors turnover ratio, which stands at 4.20 times, the lowest in its recent history. In terms of quality metrics, Sanjivani Paranteral has transitioned from an average to a good quality grade, supported by robust sales growth and EBIT growth over the past five years.

On the valuation front, the stock is categorized as very expensive, with a price-to-earnings (PE) ratio of 35.68 and an enterprise value to EBITDA of 28.26. Despite these high valuations, the company has demonstrated strong management efficiency, reflected in a return on equity (ROE) of 21.72%.

Overall, the recent evaluation adjustment highlights a complex picture for Sanjivani Paranteral, balancing strong growth metrics with valuation concerns.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.